SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant social media buzz as traders debate its potential as a high-growth Layer-1 alternative to Solana, with many highlighting its integration into institutional products and recent developments within its ecosystem. Community discussions are split between bullish sentiment fueled by institutional accumulation and skepticism from those wary of market volatility and recent price fluctuations.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively debating the potential for a breakout or consolidation phase as $PEPE trends alongside broader meme coin volatility. Traders are expressing mixed sentiments, with some focusing on long-term accumulation strategies during pullbacks while others remain skeptical about the coin's price stability.

StupidCoin

StupidCoin is gaining significant traction within the Solana ecosystem as traders rally behind its active community-led development and viral marketing efforts. Enthusiasts are highlighting the project's recent growth, community collaborations, and ecosystem integrations as key drivers for heightened market interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which aligned on the submission path and label strategy for sonelokimab in hidradenitis suppurativa. Community discussion is focused on the upcoming VELA 52-week durability data and the potential for a favorable BLA submission in late 2026, with investors actively debating the competitive positioning against existing treatments and anticipating a potential price re-rating.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is trending as the community rallies around its unique 'tokenized self-belief' narrative, emphasizing grit and holding conviction during market volatility. Enthusiasts are actively highlighting the project's growth on the Base chain and speculating on potential exchange listings, with many members bonding over the core 'I got that dog in me' spirit.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

KARRAT is gaining community attention as investors anticipate a major breakout driven by its deep integration into the Web3 gaming sector, specifically through the StudioChain infrastructure and its flagship title, My Pet Hooligan. Many participants are actively accumulating tokens, citing strong strategic partnerships with major AI and tech firms as a primary catalyst for long-term growth despite recent market volatility.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This Nakamoto/Avalanche hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as instant transaction finality, staking rewards, extensibility through subnets, and flexible protocol governance.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrades, allowing for more rapid, iterative development

eCash

eCash (XEC) is seeing significant community engagement as the network prepares for the November 15th Avalanche Pre-Consensus upgrade, which aims to deliver instant transaction finality. Builders and stakers are actively discussing these infrastructure milestones and the ongoing expansion of the eCash ecosystem.

Honda Motor Co., Ltd. engages in the manufacture and sale of automobiles, motorcycles, and power products. It operates through the following segments: Automobile, Motorcycle, Financial Services, and Power Product and Other Businesses. The Automobile segment manufactures and sells automobiles and related accessories. The Motorcycle segment handles all-terrain vehicles, motorcycle business, and related parts. The Financial Services segment provides financial and insurance services. The Power Product and Other Businesses segment offers power products and relevant parts. The company was founded by Soichiro Honda on September 24, 1948 and is headquartered in Tokyo, Japan.

Honda Motor - ADR

Honda Motor Co., Ltd.

Honda is experiencing significant volatility as the company grapples with an abrupt cancellation of its AFEELA EV joint venture with Sony and a massive writedown of its electric vehicle strategy. Community sentiment is mixed, with some investors focusing on the company's long-term reliability and value in hybrid markets, while others express frustration over its lagging pace in the global EV race compared to Chinese competitors.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 design for its lead drug candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some investors are optimistic about the upcoming trial path and orphan drug designation, the community is currently debating the stock's volatility and widespread skepticism surrounding the heavy automated bot activity on discussion boards.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing heightened market attention driven by institutional interest following its inclusion in a T. Rowe Price crypto ETF filing, though the community remains sharply divided between long-term holders citing Shibarium utility and skeptics calling the project a stagnant asset. Active discussions are dominated by debates over token burn mechanisms, ongoing layer-2 development, and speculative rotation into smaller meme-themed projects on platforms like Base.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

The war on mental illness may be entering its most dramatic turning point in a generation. On April 18, President Trump signed an Executive Order directing the FDA to accelerate research and approval pathways for psychedelic therapies including psilocybin and ibogaine, calling them a potential lifeline for Americans suffering from debilitating conditions. Six days later, the FDA followed with formal priority review designations for qualifying psychedelic treatments, signaling that this once fringe sector of biotechnology has landed squarely in the mainstream of U.S. drug policy.Shares of ...

<ul class="summary-bullets"><li>Psyga Bio has seven approved Phase 2 clinical trials across areas such as mental health, addiction, and neurological disorders.</li><li>The deal also includes a licensed manufacturing facility capable of producing pharmaceutical-grade psychedelic compounds.</li><li>The deal comes days after the U.S. expedited the research and treatment using psychedelic therapies.</li></ul>Shares of XTL Biopharmaceuticals (XTLB) surged more than 90% on Wednesday, breaching the 200-day moving average for the first time in more than three months, after the biotech firm signaled a major move into the fast-growing psychedelic medicine industry by announcing the acquisition of Psyga Bio.<a href="https://stocktwits.com/symbol/XTLB">XTLB shares</a> recorded their biggest single-day jump since Dec. 26, 2026.<h2 class="st-heading-2">Expansion Into Psychedelic Therapeutics</h2>The acquisition will give XTL full ownership of Psyga, a company focused on developing treatments derived from psychedelic compounds like Psilocybin and Ibogaine. Psyga brings a strong pipeline, including seven approved Phase 2 clinical trials that are expected to begin patient enrollment soon across areas such as mental health, addiction, and neurological disorders.The deal also includes a licensed manufacturing facility capable of producing pharmaceutical-grade psychedelic compounds.Under the agreement, Psyga shareholders will receive equity representing 40% of XTL, with additional shares tied to key clinical and commercial milestones. No upfront cash payment will be made, the company said. Following the deal, Psyga will operate as a wholly owned subsidiary of XTL.<h2 class="st-heading-2">Regulatory Tailwinds Boost Sector</h2>The deal comes as regulatory support for psychedelic therapies is gaining momentum in the U.S. On April 18, 2026, President Donald Trump signed an order directing the U.S. Food and Drug Administration (FDA) to expedite research, approvals, and access to treatments such as Psilocybin and Ibogaine.Soon after, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/fda-fast-tracks-psychedelic-research-trump-executive-order-cmps-help-stocks/cZBh5Y9Rec3">introduced</a> faster review pathways and priority actions for these therapies, improving the sector's outlook. The agency said this move will help expand the use of psychedelic-based medicines for conditions such as PTSD, treatment-resistant depression, and major depressive disorder.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user highlighted a flag pattern on the charts and added that if the stock breaks above $4.30, a major upside is on the cards.<stembedurl>https://stocktwits.com/profitcatcher/message/651757764</stembedurl>The stock has gained around 34% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

XTLB Stock Surges 90%, Breaches 200-DMA For First Time In Over 3 Months – Here’s What The Acquisition Of Psyga Bio Brings To The Table

XTL Biopharmaceuticals announced the acquisition of Psyga Bio to gain a major foothold in the psychedelic therapeutics industry.

Equity

Wall Street’s Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets

The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine.  $NEO, $TGNT, $XTLB, $SAGT, $PRCH, $AKAN

<ul class="summary-bullets"><li>XTL will acquire NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. &nbsp;</li><li>NeuroNOS is a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD) and other neurodevelopmental and neurodegenerative disorders.&nbsp;</li><li>NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.</li></ul>Shares of Beyond Air, Inc. (XAIR) rallied 149% on Tuesday after XTL Biopharmaceuticals Ltd. (XTLB) announced a deal to acquire a majority stake in its subsidiary NeuroNOS Ltd.Under the deal, IP portfolio company XTL will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.beyondair.net/news-events/press-releases?i=161064">acquire</a> 85% of NeuroNOS, a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD), and other neurodevelopmental and neurodegenerative disorders.Shares of XTLB gained 51% at the time of writing.<h2 class="st-heading-2">Deal Terms</h2>As part of the deal, XTL will acquire 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million.XTL noted that NeuroNOS's drug development platform is designed to address the underlying molecular mechanisms driving autism unlike treatments based on behavioral symptoms. NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.According to BeyondAir, autism spectrum disorder affects about one in 31 children in the U.S. and has been rising dramatically. No FDA-approved therapies aimed at disease modification exist for the disorder at present.The company also noted that the Trump administration has, in recent times, emphasized support for new medicines aimed at treating autism.“The administration has allocated $50 million in new NIH funding for autism research initiatives. This recognition at the federal level signals a fundamental shift in regulatory priorities and resource allocation toward autism research and treatment development,” BeyondAir said in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around XAIR and XTLB rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user applauded the deal, opining that selling most of the unit will help de-risk Beyond Air’s investment while also creating potential future revenue streams.<stembedurl>https://www.stocktwits.com/stockpro2010/message/641694012</stembedurl><a href="https://stocktwits.com/symbol/XAIR">XAIR stock</a> has fallen 70% this year while <a href="https://stocktwits.com/symbol/XTLB">XTLB</a> dropped 44% in the same period.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/travere-therapeutics-stock-slumps-after-fda-extends-drug-review-timeline-to-april/cmUXhZuR4IK">Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

XAIR Stock More Than Doubled Today — What’s Driving The Rally?

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.

CommScope Holding Company Inc. (COMM) witnessed retail sentiment and message volume hit a one-year high on Stocktwits on Monday after the company struck a deal to divest its Connectivity and Cable Solutions (CCS) division to Amphenol Corporation (APH) in an all-cash transaction valued at $10.5 billion.&nbsp;The transaction is slated to close in the first half of 2026, pending shareholder approval and regulatory clearance.&nbsp;<a href="https://stocktwits.com/symbol/COMM">CommScope stock</a> traded over 91% higher by Monday afternoon. Retail sentiment around the stock shifted to ‘extremely bullish’ (98/100) from ‘bullish’ territory the previous day. Message volume jumped to ‘extremely high’ (96/100) from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:953/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_135903_png_0a79ce6cc2.webp" alt="COMM’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="953" height="104"><figcaption>COMM’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user lauded the buyout.&nbsp;<stembedurl>https://stocktwits.com/ghcb1981/message/623597970</stembedurl>Another user expects the stock to finish above $15, saying ‘Get in while it’s cheap!’<stembedurl>https://stocktwits.com/SvenneKaare/message/623621273</stembedurl>The agreement marks a major reshaping of CommScope’s business portfolio as it focuses on core operations. The company anticipates net proceeds of roughly $10 billion once taxes and fees are accounted for, and a significant portion will go toward paying off all existing debt and redeeming its preferred shares, currently held by The Carlyle Group Inc. (CG).&nbsp;The company noted it will retain some leverage on its remaining operations but expects to hold a substantial cash reserve after the transaction.Once the sale is completed and all financial obligations are settled, CommScope intends to return surplus funds to investors. A dividend distribution is expected within 60 to 90 days of closing, though final details, including the exact payout, will be determined later.The company also reported its second-quarter (Q2) revenue of $1.39 billion, beating the analysts’ consensus estimate of $1.25 billion, as per Fiscal AI data. CommScope stock has gained over 188% year-to-date and over 643% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-s-podcast-bet-falters/chrXAm9Rdcb">Amazon’s Podcast Bet Falters As Job Cuts Loom At Wondery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo for Commscope is displayed during the Tech Show at ExCel London on March 12, 2025 in London, England.

CommScope Stock Rockets 91% As Retail Bulls Cheer $10.5B Asset Sale: ‘Get In While It’s Cheap!’

Once the sale is completed and all financial obligations are settled, CommScope intends to return surplus funds to investors. 

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

X.T.L. Biopharmaceuticals Ltd. - ADR

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

XTLB
XTL Biopharmaceuticals Ltd.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest XTLB News

XTLBXTL Biopharmaceuticals Ltd.